The positive CHMP opinion is a major derisking event for European approval. Traders should watch for the EC decision in 2H26 as the next catalyst. The PREVAIL cardiovascular outcomes trial readout will be the next major binary event for U.S. approval prospects. The stock is likely to re-rate on this regulatory progress.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 24 $29.64entry
- T+1 · 4mo ago +1.96%α +1.94% · $30.22
- T+5 · 4mo ago −3.98%α −4.35% · $28.46
- T+20 · 3mo ago −5.97%α −9.60% · $27.87
- T+60 · 29d ago −30.94%α −34.23% · $20.47
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
NewAmsterdam Pharma announced that the EMA's CHMP has adopted a positive opinion recommending marketing authorization for Ubeslo (obicetrapib monotherapy) and Evlarco (obicetrapib plus ezetimibe fixed-dose combination) in Europe. The European Commission is expected to issue a final decision in 2H26, and if approved, this would enable commercialization of obicetrapib across EU member states, Iceland, Liechtenstein, and Norway, unlocking milestone payments of up to €833 million for NewAmsterdam plus tiered double-digit royalties on net sales in the Menarini territory.
Key Facts
- CHMP adopted a positive opinion recommending marketing authorization for Ubeslo (obicetrapib 10 mg monotherapy) and Evlarco (10 mg obicetrapib plus 10 mg ezetimibe fixed-dose combination).
- Recommendation is supported by Phase 3 BROADWAY, BROOKLYN, and TANDEM data showing up to ~40% LDL-C reduction with obicetrapib monotherapy and ~50% with the combination vs placebo.
- European Commission decision expected in 2H26; if granted, authorization applies across all EU member states plus Iceland, Liechtenstein, and Norway.
- NewAmsterdam is entitled to up to €833 million in clinical, regulatory, and commercial milestones plus tiered double-digit royalties (low double-digits to mid-twenties) on net sales in the Menarini territory.
- Menarini holds exclusive commercialization rights for obicetrapib in Europe and is responsible for regulatory interactions and commercialization.
Financial Impact
Up to €833 million in milestone payments plus tiered double-digit percentage royalties on European net sales
Risk Factors
- EC may not grant final marketing authorization despite CHMP positive opinion
- Commercial uptake in Europe depends on pricing and reimbursement negotiations
- PREVAIL cardiovascular outcomes trial results remain a key binary risk for full commercial potential
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-315163 |
| Document: nams-ex99_1.htm | 0001193125-26-315163 |
| Document: 0001193125-26-315163-index-headers.html | 0001193125-26-315163 |
| Document: 0001193125-26-315163-index.html | 0001193125-26-315163 |
| Document: 0001193125-26-315163.txt | 0001193125-26-315163 |
Track record
8 reports on NAMS
3 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +7.23% at T+5 after the Sep 22, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $18.89 to $18.90 Now $19.46 +3.02% ▲ +0.05% −0.26% vs SPY
- Nov 4, 202612d ago Press Release Neutral 5/10 Entry $20.93 to $18.89 Now $19.46 −7.02% ▼ −9.75% −5.34% vs SPY
- Sep 29, 20266w ago 8-K Neutral 4/10 Entry $23.81 to $24.32 Now $19.46 −18.27% ▲ +2.14% +2.35% vs SPY
- Sep 22, 20267w ago SC 13D/A Bullish 5/10 Entry $22.68 to $22.74 Now $19.46 −14.20% ▲ +0.26% +0.35% vs SPY
- Sep 15, 20268w ago Insider Buy Bullish 5/10 Entry $21.18 to $21.93 Now $19.46 −8.12% ▲ +3.54% +2.41% vs SPY
- Aug 5, 202614w ago 8-K Bullish 7/10 Entry $27.42 to $27.67 Now $19.46 −29.03% ▲ +0.91% +1.07% vs SPY
- Jul 24, 202616w ago 8-K Bullish 7/10 Viewing Entry $29.64 to $30.22 Now $19.46 −34.35% ▲ +1.96% +1.94% vs SPY
- Apr 8, 202631w ago Press Release Neutral 5/10 Entry $34.01 to $35.07 Now $19.46 −42.78% ▲ +3.12% +2.54% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers